Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2021 - 2026)

Zentalis Pharmaceuticals has reported Other Non-Current Liabilities over the past 6 years, most recently at $500000.0 for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities fell 10.39% year-over-year to $500000.0; the TTM value through Mar 2026 reached $500000.0, down 10.39%, while the annual FY2025 figure was $500000.0, 41.11% down from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was $500000.0 at Zentalis Pharmaceuticals, roughly flat from $500000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $45.0 million in Q1 2022 and troughed at $500000.0 in Q2 2023.
  • A 5-year average of $4.0 million and a median of $996000.0 in 2024 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 162.0% in 2022 and later crashed 96.02% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $2.6 million in 2022, then crashed by 32.06% to $1.8 million in 2023, then plummeted by 52.3% to $849000.0 in 2024, then plummeted by 41.11% to $500000.0 in 2025, then changed by 0.0% to $500000.0 in 2026.
  • Business Quant data shows Other Non-Current Liabilities for ZNTL at $500000.0 in Q1 2026, $500000.0 in Q4 2025, and $500000.0 in Q3 2025.